Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials

Inmaculada Xu Lou; Inmaculada Xu Lou; Jiayue Chen; Jiayue Chen; Kamran Ali; Abdul Lateef Shaikh; Qilan Chen

doi:10.3389/fphar.2023.1190604

Frontiers in Pharmacology (Jun 2023)

Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials

Inmaculada Xu Lou,
Inmaculada Xu Lou,
Jiayue Chen,
Jiayue Chen,
Kamran Ali,
Abdul Lateef Shaikh,
Qilan Chen

Affiliations

Inmaculada Xu Lou: International Education College of Zhejiang Chinese Medical University, Hangzhou, China
Inmaculada Xu Lou: Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China
Jiayue Chen: Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China
Jiayue Chen: Hangzhou Clinical Medical College Internal Medicine of Traditional Chinese Medicine of Zhejiang Chinese Medical University, Hangzhou, China
Kamran Ali: Department of Oncology, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, China
Abdul Lateef Shaikh: Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Qilan Chen: Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China

DOI: https://doi.org/10.3389/fphar.2023.1190604
Journal volume & issue: Vol. 14

Abstract

Read online

Background and Objective: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, that is, characterized by cognitive decline. To date, there are no effective treatments for AD. Therefore, the objective of this study was to map new perspectives on the effects of pharmacological treatment on cognitive function and the overall psychological state in patients with AD.Methods: Two independent researchers searched for randomized clinical trials (RCTs) exploring new pharmacological approaches related to cognition in Alzheimer’s disease in adults from 2018 to 2023 in PubMed, Web of Science, Scopus, and Cochrane Library databases. A total of 17 RCTs were included in this review.Results: The results show that in recent years, new drugs have been tested in patients with Alzheimer’s disease, including masitinib, methylphenidate, levetiracetam, Jiannao Yizhi, and Huannao Yicong formulas. Most studies have been conducted in populations with mild to moderate Alzheimer’s disease.Conclusion: Although some of the drugs found suggested improvement in cognitive function, the scarcity of available studies highlights the need for further research in this area.Systematic review registration: [www.crd.york.ac.uk/prospero], identifier [CRD42023409986].

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords